Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited has achieved significant milestones in Q3 FY25, including receiving FDA 510(k) clearance for its Salix® Coronary Anatomy platform, enabling its commercial launch in the US. This clearance allows Artrya to expand its market presence by integrating its technology into major US hospital systems, providing a substantial growth opportunity. Additionally, Artrya secured three-year contracts with Sonic Healthcare and Lumus Imaging in Australia, further validating the clinical value of its platform. The company also completed a $15 million capital raise to support its operations and future developments.
More about Artrya Limited
Artrya Limited is a medical technology company specializing in the development and commercialization of an AI platform designed to detect, diagnose, and manage coronary artery disease. The company’s primary focus is on the Salix® Coronary Anatomy platform, which aims to improve the accuracy and efficiency of coronary heart disease detection through advanced imaging technologies.
YTD Price Performance: 17.92%
Average Trading Volume: 278,785
Technical Sentiment Signal: Sell
For detailed information about AYA stock, go to TipRanks’ Stock Analysis page.